These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 11022009)

  • 1. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells.
    Meyer K; Basu A; Ray R
    Virology; 2000 Oct; 276(1):214-26. PubMed ID: 11022009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of pseudotype VSV possessing HCV envelope proteins.
    Matsuura Y; Tani H; Suzuki K; Kimura-Someya T; Suzuki R; Aizaki H; Ishii K; Moriishi K; Robison CS; Whitt MA; Miyamura T
    Virology; 2001 Aug; 286(2):263-75. PubMed ID: 11485395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of N-linked glycans on intracellular transport of hepatitis C virus E1 chimeric glycoprotein and its role in pseudotype virus infectivity.
    Beyene A; Basu A; Meyer K; Ray R
    Virology; 2004 Jul; 324(2):273-85. PubMed ID: 15207615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer.
    Meyer K; Beyene A; Bowlin TL; Basu A; Ray R
    J Virol; 2004 Dec; 78(23):12838-47. PubMed ID: 15542636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pseudotype hepatitis C virus enters immature myeloid dendritic cells through the interaction with lectin.
    Kaimori A; Kanto T; Kwang Limn C; Komoda Y; Oki C; Inoue M; Miyatake H; Itose I; Sakakibara M; Yakushijin T; Takehara T; Matsuura Y; Hayashi N
    Virology; 2004 Jun; 324(1):74-83. PubMed ID: 15183055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.
    Lagging LM; Meyer K; Owens RJ; Ray R
    J Virol; 1998 May; 72(5):3539-46. PubMed ID: 9557633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.
    Lavillette D; Tarr AW; Voisset C; Donot P; Bartosch B; Bain C; Patel AH; Dubuisson J; Ball JK; Cosset FL
    Hepatology; 2005 Feb; 41(2):265-74. PubMed ID: 15660396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus E1 envelope glycoprotein interacts with apolipoproteins in facilitating entry into hepatocytes.
    Mazumdar B; Banerjee A; Meyer K; Ray R
    Hepatology; 2011 Oct; 54(4):1149-56. PubMed ID: 21735466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of recombinant vesicular stomatitis viruses encoding mutant glycoproteins demonstrate a critical role for maintaining a high pH threshold for membrane fusion in viral fitness.
    Fredericksen BL; Whitt MA
    Virology; 1998 Jan; 240(2):349-58. PubMed ID: 9454708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus envelope glycoproteins and potential for vaccine development.
    Beyene A; Basu A; Meyer K; Ray R
    Vox Sang; 2002 Aug; 83 Suppl 1():27-32. PubMed ID: 12617098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro interaction between hepatitis C virus (HCV) envelope glycoprotein E2 and serum lipoproteins (LPs) results in enhanced cellular binding of both HCV E2 and LPs.
    Wunschmann S; Muller HM; Stipp CS; Hemler ME; Stapleton JT
    J Infect Dis; 2006 Oct; 194(8):1058-67. PubMed ID: 16991080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection.
    Burioni R; Mancini N; Carletti S; Perotti M; Grieco A; Canducci F; Varaldo PE; Clementi M
    Virology; 2004 Oct; 327(2):242-8. PubMed ID: 15351212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus envelope protein E2 binds to CD81 of tamarins.
    Allander T; Forns X; Emerson SU; Purcell RH; Bukh J
    Virology; 2000 Nov; 277(2):358-67. PubMed ID: 11080483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.
    Basu A; Beyene A; Meyer K; Ray R
    J Virol; 2004 May; 78(9):4478-86. PubMed ID: 15078928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sulfated homologues of heparin inhibit hepatitis C virus entry into mammalian cells.
    Basu A; Kanda T; Beyene A; Saito K; Meyer K; Ray R
    J Virol; 2007 Apr; 81(8):3933-41. PubMed ID: 17287282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein.
    Meyer K; Basu A; Przysiecki CT; Lagging LM; Di Bisceglie AM; Conley AJ; Ray R
    J Virol; 2002 Mar; 76(5):2150-8. PubMed ID: 11836392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.
    Bartosch B; Vitelli A; Granier C; Goujon C; Dubuisson J; Pascale S; Scarselli E; Cortese R; Nicosia A; Cosset FL
    J Biol Chem; 2003 Oct; 278(43):41624-30. PubMed ID: 12913001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Glycoprotein-Mediated Entry of Severe Fever with Thrombocytopenia Syndrome Virus.
    Tani H; Shimojima M; Fukushi S; Yoshikawa T; Fukuma A; Taniguchi S; Morikawa S; Saijo M
    J Virol; 2016 Jun; 90(11):5292-5301. PubMed ID: 26984731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterisation of the differences between hepatitis C virus genotype 3 and 1 glycoproteins.
    Shaw ML; McLauchlan J; Mills PR; Patel AH; McCruden EA
    J Med Virol; 2003 Jul; 70(3):361-72. PubMed ID: 12766998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 293 cells over-expressing human ADI1 and CD81 are permissive for serum-derived hepatitis C virus infection.
    Cheng JC; Yeh YJ; Pai LM; Chang ML; Yeh CT
    J Med Virol; 2009 Sep; 81(9):1560-8. PubMed ID: 19626614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.